Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


03.04.2017

1 AJR Am J Roentgenol
2 Am J Clin Pathol
1 Am J Epidemiol
3 Am J Surg
3 BMC Cancer
4 BMJ
3 Br J Cancer
4 Breast Cancer (Dove Med Press)
9 Breast Cancer Res
10 Breast Cancer Res Treat
2 Cancer Chemother Pharmacol
1 Cancer Res
1 Clin Breast Cancer
2 Clin Cancer Res
1 Clin Exp Metastasis
4 Eur J Cancer
2 Gene
1 Int J Cancer
3 Int J Oncol
3 J Surg Oncol
1 Lancet Oncol
1 Mod Pathol
1 Nature
2 Oncol Rep
1 Pathology
1 PLoS Genet
1 PLoS One
1 Radiother Oncol
1 Science


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. EOM HJ, Cha JH, Choi WJ, Chae EY, et al
    Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    AJR Am J Roentgenol. 2017 Mar 28:1-6. doi: 10.2214/AJR.16.17125.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  2. LIN D, Genzen J
    Comparison of Breast Cancer Tumor Marker Test Results: A Retrospective Analysis of Paired CA 15-3 and CA 27.29 Testing at a National Reference Laboratory.
    Am J Clin Pathol. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format    

  3. SOLOMON JP, Dell'Aquila M, Fadare O, Hasteh F, et al
    Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Am J Clin Pathol. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available


    Am J Epidemiol

  4. WIRTZ HS, Calip GS, Buist DS, Gralow JR, et al
    Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors.
    Am J Epidemiol. 2017 Mar 1:1-12. doi: 10.1093.
    PubMed     Text format     Abstract available


    Am J Surg

  5. WARD EP, Wang J, Mendez N, Yang J, et al
    Utilization of iron (III)-doped nanoshells for in vivo marking of nonpalpable tumors using a VX2 rabbit model.
    Am J Surg. 2016;212:1140-1146.
    PubMed     Text format     Abstract available

  6. ACOTT AA, Mancino AT
    Flat epithelial atypia on core needle biopsy, must we surgically excise?
    Am J Surg. 2016;212:1211-1213.
    PubMed     Text format     Abstract available

  7. LALLEMAND M, Barron M, Bingham J, Mosier A, et al
    The true impact of breast magnetic resonance imaging on the management of in situ disease: more is not better.
    Am J Surg. 2017;213:127-131.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. ARIAANS G, Jalving M, Vries EG, Jong S, et al
    Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
    BMC Cancer. 2017;17:232.
    PubMed     Text format     Abstract available

  9. KURBEL S, Dmitrovic B, Marjanovic K, Vrbanec D, et al
    Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology.
    BMC Cancer. 2017;17:231.
    PubMed     Text format     Abstract available

  10. OBERGUGGENBERGER A, Meraner V, Sztankay M, Beer B, et al
    Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
    BMC Cancer. 2017;17:226.
    PubMed     Text format     Abstract available


    BMJ

  11. ARIE S
    MP and former GP challenges Uruguay's compulsory breast screening programme.
    BMJ. 2016;355:i6624.
    PubMed     Text format    

  12. DESAI S, Jena AB
    Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial.
    BMJ. 2016;355:i6357.
    PubMed     Text format     Abstract available

  13. FRICKER J
    Umberto Veronesi.
    BMJ. 2016;355:i6765.
    PubMed     Text format    

  14. WARREN P
    Adele Francis.
    BMJ. 2017;356:j728.
    PubMed     Text format    


    Br J Cancer

  15. CHIARELLI AM, Muradali D, Blackmore KM, Smith CR, et al
    Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  16. SHEN J, Liao Y, Hopper JL, Goldberg M, et al
    Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  17. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  18. NANDIKOLLA AG, Venugopal S, Anampa J
    Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature.
    Breast Cancer (Dove Med Press). 2017;9:207-215.
    PubMed     Text format     Abstract available

  19. BUXANT F, Kindt N, Noel JC, Laurent G, et al
    Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy.
    Breast Cancer (Dove Med Press). 2017;9:171-175.
    PubMed     Text format     Abstract available

  20. CHAN TY, Tan PW, Tang JI
    Intensity-modulated radiation therapy for early-stage breast cancer: is it ready for prime time?
    Breast Cancer (Dove Med Press). 2017;9:177-183.
    PubMed     Text format     Abstract available

  21. JERNSTROM S, Hongisto V, Leivonen SK, Due EU, et al
    Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response.
    Breast Cancer (Dove Med Press). 2017;9:185-198.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  22. DAI M, Al-Odaini AA, Arakelian A, Rabbani SA, et al
    Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion.
    Breast Cancer Res. 2017;19:40.
    PubMed     Text format    

  23. DAI M, Al-Odaini AA, Fils-Aime N, Villatoro MA, et al
    Erratum to: Cyclin D1 cooperates with p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local invasion.
    Breast Cancer Res. 2017;19:43.
    PubMed     Text format    

  24. NAGALINGAM A, Arbiser JL, Bonner MY, Saxena NK, et al
    Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis.
    Breast Cancer Res. 2017;19:39.
    PubMed     Text format    

  25. FLAHERTY RL, Owen M, Fagan-Murphy A, Intabli H, et al
    Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer.
    Breast Cancer Res. 2017;19:35.
    PubMed     Text format     Abstract available

  26. PADAMSEE TJ, Wills CE, Yee LD, Paskett ED, et al
    Decision making for breast cancer prevention among women at elevated risk.
    Breast Cancer Res. 2017;19:34.
    PubMed     Text format     Abstract available

  27. AURE MR, Vitelli V, Jernstrom S, Kumar S, et al
    Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
    Breast Cancer Res. 2017;19:44.
    PubMed     Text format     Abstract available

  28. LEE YF, Miller LD, Chan XB, Black MA, et al
    Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
    Breast Cancer Res. 2017;19:42.
    PubMed     Text format    

  29. WU Z, Shen S, Zhang Z, Zhang W, et al
    Erratum to: Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-small ka, CyrillicB mediated matrix metalloproteinase-1 gene regulation.
    Breast Cancer Res. 2017;19:41.
    PubMed     Text format    

  30. HOLEN I, Whitworth J, Nutter F, Evans A, et al
    Erratum to: Loss of plakoglobin promotes cell-cell contact, increased invasion and breast cancer cell dissemination in vivo.
    Breast Cancer Res. 2017;19:37.
    PubMed     Text format    


    Breast Cancer Res Treat

  31. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2017 Mar 24. doi: 10.1007/s10549-017-4202.
    PubMed     Text format     Abstract available

  32. KRAMMER J, Pinker-Domenig K, Robson ME, Gonen M, et al
    Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Mar 25. doi: 10.1007/s10549-017-4198.
    PubMed     Text format     Abstract available

  33. WU Y, Tran T, Dwabe S, Sarkissyan M, et al
    A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4211.
    PubMed     Text format     Abstract available

  34. HOLCAKOVA J, Nekulova M, Orzol P, Nenutil R, et al
    DeltaNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4216.
    PubMed     Text format     Abstract available

  35. LIM Y, Ko ES, Han BK, Ko EY, et al
    Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4217.
    PubMed     Text format     Abstract available

  36. CICCARESE M, Fabi A, Moscetti L, Cazzaniga ME, et al
    Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4213.
    PubMed     Text format     Abstract available

  37. WOLLSCHLAGER D, Merzenich H, Schwentner L, Janni W, et al
    Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study).
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4215.
    PubMed     Text format     Abstract available

  38. MOSHINA N, Sebuodegard S, Hofvind S
    Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program?
    Breast Cancer Res Treat. 2017 Mar 29. doi: 10.1007/s10549-017-4214.
    PubMed     Text format     Abstract available

  39. KAWAGUCHI H, Masuda N, Nakayama T, Aogi K, et al
    Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4212.
    PubMed     Text format     Abstract available

  40. HAMURCU Z, Kahraman N, Ashour A, Ozpolat B, et al
    FOXM1 transcriptionally regulates expression of integrin beta1 in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Mar 30. doi: 10.1007/s10549-017-4207.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  41. CHE J, Huang Y, Xu C, Zhang P, et al
    Increased ceramide production sensitizes breast cancer cell response to chemotherapy.
    Cancer Chemother Pharmacol. 2017 Mar 29. doi: 10.1007/s00280-017-3292.
    PubMed     Text format     Abstract available

  42. ROCCA A, Cecconetto L, Passardi A, Melegari E, et al
    Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3279.
    PubMed     Text format     Abstract available


    Cancer Res

  43. TEMKO DP, Cheng YK, Polyak K, Michor F, et al
    Mathematical modeling links pregnancy-associated changes and breast cancer risk.
    Cancer Res. 2017 Mar 30. pii: canres.2504.2016.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  44. WANG CH, Chang CJ, Yeh KY, Chang PH, et al
    The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2017 Feb 16. pii: S1526-8209(17)30086.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  45. PITRODA S, Bao R, Andrade J, Weichselbaum RR, et al
    Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer.
    Clin Cancer Res. 2017 Mar 24. pii: clincanres.2845.2016.
    PubMed     Text format     Abstract available

  46. SOMLO G, Frankel P, Arun B, Ma CX, et al
    Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 29. pii: clincanres.2714.2016.
    PubMed     Text format     Abstract available


    Clin Exp Metastasis

  47. SZEKELY B, Nagy ZI, Farago Z, Kiss O, et al
    Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.
    Clin Exp Metastasis. 2017;34:103-113.
    PubMed     Text format     Abstract available


    Eur J Cancer

  48. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available

  49. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available

  50. VAN RAMSHORST MS, van Werkhoven E, Mandjes IA, Schot M, et al
    Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
    Eur J Cancer. 2017;74:47-54.
    PubMed     Text format     Abstract available

  51. NATORI A, Ethier JL, Amir E, Cescon DW, et al
    Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
    Eur J Cancer. 2017;77:40-47.
    PubMed     Text format     Abstract available


    Gene

  52. ZHANG K, Wang YW, Wang YY, Song Y, et al
    Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
    Gene. 2017 Mar 27. pii: S0378-1119(17)30218-4. doi: 10.1016/j.gene.2017.
    PubMed     Text format     Abstract available

  53. REZENDE LM, Marson FA, Lima CS, Bertuzzo CS, et al
    Corrigendum to "Variants of estrogen receptor alpha and beta genes modify the severity of sporadic breast cancer" [Gene 608C (2017) 73-78].
    Gene. 2017 Mar 28. pii: S0378-1119(17)30210-X. doi: 10.1016/j.gene.2017.
    PubMed     Text format    


    Int J Cancer

  54. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
    Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
    PubMed     Text format     Abstract available


    Int J Oncol

  55. XI J, Feng J, Li Q, Li X, et al
    The long non-coding RNA lncFOXO1 suppresses growth of human breast cancer cells through association with BAP1.
    Int J Oncol. 2017 Mar 24. doi: 10.3892/ijo.2017.3933.
    PubMed     Text format     Abstract available

  56. GIL EY, Jo UH, Jeong H, Whang YM, et al
    [Corrigendum] Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer.
    Int J Oncol. 2017 Mar 7. doi: 10.3892/ijo.2017.3900.
    PubMed     Text format     Abstract available

  57. OKAMOTO K, Tanaka Y, Tsuneoka M
    SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
    Int J Oncol. 2017 Mar 10. doi: 10.3892/ijo.2017.3908.
    PubMed     Text format     Abstract available


    J Surg Oncol

  58. GERVAIS MK, Maki E, Schiller DE, Crystal P, et al
    Preoperative MRI of the breast and ipsilateral breast tumor recurrence: Long-term follow up.
    J Surg Oncol. 2017;115:231-237.
    PubMed     Text format     Abstract available

  59. VIEIRA RA, da Silva KM, de Oliveira-Junior I, de Lima MA, et al
    ITADE flap after mastectomy for locally advanced breast cancer: A good choice for mid-sized defects of the chest wall, based on a systematic review of thoracoabdominal flaps.
    J Surg Oncol. 2017 Mar 27. doi: 10.1002/jso.24619.
    PubMed     Text format     Abstract available

  60. SCHULZ-WENDTLAND R, Harz M, Meier-Meitinger M, Brehm B, et al
    Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping).
    J Surg Oncol. 2017;115:238-242.
    PubMed     Text format     Abstract available


    Lancet Oncol

  61. BURKI TK
    Sacituzumab govitecan activity in advanced breast cancer.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30232.
    PubMed     Text format    


    Mod Pathol

  62. PANG JB, Savas P, Fellowes AP, Mir Arnau G, et al
    Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
    Mod Pathol. 2017 Mar 24. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    Nature


  63. Cancer: How fat boosts breast cancer.
    Nature. 2017;543:593.
    PubMed     Text format    


    Oncol Rep

  64. THULASIRAMAN P, Garriga G, Danthuluri V, McAndrews DJ, et al
    Activation of the CRABPII/RAR pathway by curcumin induces retinoic acid mediated apoptosis in retinoic acid resistant breast cancer cells.
    Oncol Rep. 2017 Mar 8. doi: 10.3892/or.2017.5495.
    PubMed     Text format     Abstract available

  65. WOKOUN U, Hellriegel M, Emons G, Grundker C, et al
    Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
    Oncol Rep. 2017 Mar 6. doi: 10.3892/or.2017.5491.
    PubMed     Text format     Abstract available


    Pathology

  66. FICIAL M, Parisi A, Remo A, Vasori S, et al
    Usefulness of breast cytology after lipofilling.
    Pathology. 2016;48:746-747.
    PubMed     Text format    


    PLoS Genet

  67. HOFFMAN JD, Graff RE, Emami NC, Tai CG, et al
    Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk.
    PLoS Genet. 2017;13:e1006690.
    PubMed     Text format     Abstract available


    PLoS One

  68. STANKEVICINS L, Barat A, Dessen P, Vassetzky Y, et al
    The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model.
    PLoS One. 2017;12:e0173756.
    PubMed     Text format     Abstract available


    Radiother Oncol

  69. FRANCOLINI G, Thomsen MS, Yates ES, Kirkove C, et al
    Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1.
    Radiother Oncol. 2017 Mar 25. pii: S0167-8140(17)30107.
    PubMed     Text format     Abstract available


    Science

  70. TOSKA E, Osmanbeyoglu HU, Castel P, Chan C, et al
    PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
    Science. 2017;355:1324-1330.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: